source
- BlossomHill and Latigo lead a surge of biotech IPOs after summer dry spellAfter a seven‑month lull that left no biotech companies on the public markets last summer, the sector is seeing renewed activity. BlossomHill Therapeutics and Latigo have filed to list on Nasdaq,…
- GSK drops camlipant cough drug after mixed Phase 3 resultsGSK announced it is halting development of camlipant, an experimental chronic cough medicine it acquired in a $2 billion purchase three years ago. The decision follows two Phase 3 trials that show…